Analysis: Biotech buys seen in cancer, immunology, neurology - Reuters
Wed, 13 Jul 2011 17:01Another cancer drug developer with an expensive share price is Dendreon, which last year launched sales of Provenge, a novel vaccine treatment for prostate cancer that costs $93000 per year. The company's shares have gained 10 percent in 2011. ...
Top Biotech Picks of High Alpha Funds - Seeking Alpha
Thu, 14 Jul 2011 16:43Top guru funds that sold REGN include Baupost Group LLC ($45 million) and SAC Capital Advisors LP ($1 million). The mean analyst target is $65, with a high target of $78, well above the current $57 price; and of the fourteen analysts covering the stock ...
US HOT STOCKS: JP Morgan, ConocoPhillips, Southern Union, Marriott - Wall Street Journal
Thu, 14 Jul 2011 14:53Barclays Capital cut its stock-investment rating on Netgear Inc. (NTGR, $41.06, -$1.92, -4.47%) to equalweight from overweight, citing valuation, noting the company's shares are up about 120% over the past year. The firm also said Netgear's focus on ...
Newspaper Briefing, including 'FBI to investigate News Corp hacking ... - Proactive Investors UK
Fri, 15 Jul 2011 06:16Year-on-year revenues were up by almost third, while adjusted earnings per share rose 36%. In after market trading, Googles share price leapt by 12%. Where did Mr Page over-deliver? The simple answer is that the core search advertising business is ...
Midyear Fund Report: Emerging markets spur some hot sectors - USA Today
Wed, 06 Jul 2011 00:43"It's a conundrum," says Peter Nielsen, portfolio manager at Saturna Capital. "But currencies are strong for a good reason — they are, frankly, where the growth is." US stock funds haven't ignored growth in emerging markets. Some large-company growth ...
Sector:
